Switch theme
Sign up to access all valuation multiples
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
2019
214
LTM Revenue $7.0M
LTM EBITDA -$182M
$132M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Prime Medicine has a last 12-month revenue (LTM) of $7.0M and a last 12-month EBITDA of -$182M.
In the most recent fiscal year, Prime Medicine achieved revenue of $3.0M and an EBITDA of -$196M.
Prime Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Prime Medicine valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.0M | XXX | $3.0M | XXX | XXX | XXX |
| Gross Profit | $7.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$182M | XXX | -$196M | XXX | XXX | XXX |
| EBITDA Margin | -2605% | XXX | -6582% | XXX | XXX | XXX |
| EBIT | -$188M | XXX | -$202M | XXX | XXX | XXX |
| EBIT Margin | -2695% | XXX | -6787% | XXX | XXX | XXX |
| Net Profit | -$186M | XXX | -$196M | XXX | XXX | XXX |
| Net Margin | -2664% | XXX | -6567% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Prime Medicine's stock price is $1.
Prime Medicine has current market cap of $155M, and EV of $132M.
See Prime Medicine trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $132M | $155M | XXX | XXX | XXX | XXX | $-1.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Prime Medicine has market cap of $155M and EV of $132M.
Prime Medicine's trades at 44.4x EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate Prime Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Prime Medicine has a P/E ratio of -0.8x.
See valuation multiples for Prime Medicine and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $155M | XXX | $155M | XXX | XXX | XXX |
| EV (current) | $132M | XXX | $132M | XXX | XXX | XXX |
| EV/Revenue | 18.9x | XXX | 44.4x | XXX | XXX | XXX |
| EV/EBITDA | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 18.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.8x | XXX | -0.8x | XXX | XXX | XXX |
| EV/FCF | -1.0x | XXX | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPrime Medicine's last 12 month revenue growth is 172%
Prime Medicine's revenue per employee in the last FY averaged $14K, while opex per employee averaged $1.0M for the same period.
Prime Medicine's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Prime Medicine's rule of X is -2174% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Prime Medicine and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 172% | XXX | 207% | XXX | XXX | XXX |
| EBITDA Margin | -2605% | XXX | -6582% | XXX | XXX | XXX |
| EBITDA Growth | -13% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -6410% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2174% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $14K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5206% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 6887% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prime Medicine acquired XXX companies to date.
Last acquisition by Prime Medicine was XXXXXXXX, XXXXX XXXXX XXXXXX . Prime Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Prime Medicine founded? | Prime Medicine was founded in 2019. |
| Where is Prime Medicine headquartered? | Prime Medicine is headquartered in United States of America. |
| How many employees does Prime Medicine have? | As of today, Prime Medicine has 214 employees. |
| Who is the CEO of Prime Medicine? | Prime Medicine's CEO is Dr. Allan Reine, M.D.. |
| Is Prime Medicine publicy listed? | Yes, Prime Medicine is a public company listed on NAS. |
| What is the stock symbol of Prime Medicine? | Prime Medicine trades under PRME ticker. |
| When did Prime Medicine go public? | Prime Medicine went public in 2022. |
| Who are competitors of Prime Medicine? | Similar companies to Prime Medicine include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Prime Medicine? | Prime Medicine's current market cap is $155M |
| What is the current revenue of Prime Medicine? | Prime Medicine's last 12 months revenue is $7.0M. |
| What is the current revenue growth of Prime Medicine? | Prime Medicine revenue growth (NTM/LTM) is 172%. |
| What is the current EV/Revenue multiple of Prime Medicine? | Current revenue multiple of Prime Medicine is 18.9x. |
| Is Prime Medicine profitable? | Yes, Prime Medicine is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Prime Medicine? | Prime Medicine's last 12 months EBITDA is -$182M. |
| What is Prime Medicine's EBITDA margin? | Prime Medicine's last 12 months EBITDA margin is -2605%. |
| What is the current EV/EBITDA multiple of Prime Medicine? | Current EBITDA multiple of Prime Medicine is -0.7x. |
| What is the current FCF of Prime Medicine? | Prime Medicine's last 12 months FCF is -$138M. |
| What is Prime Medicine's FCF margin? | Prime Medicine's last 12 months FCF margin is -1981%. |
| What is the current EV/FCF multiple of Prime Medicine? | Current FCF multiple of Prime Medicine is -1.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
